CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · Real-Time Price · USD
0.390
-0.020 (-4.85%)
At close: Apr 28, 2026, 4:00 PM EDT
0.390
-0.000 (-0.03%)
After-hours: Apr 28, 2026, 6:39 PM EDT

CollPlant Biotechnologies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Revenue
2.370.5210.960.315.64
Upgrade
Revenue Growth (YoY)
360.39%-95.30%3565.22%-98.09%154.86%
Upgrade
Cost of Revenue
0.841.631.990.42.01
Upgrade
Gross Profit
1.54-1.118.97-0.113.64
Upgrade
Selling, General & Admin
4.835.6366.745.94
Upgrade
Research & Development
8.1910.5210.4810.267.63
Upgrade
Operating Expenses
13.0216.1416.481713.57
Upgrade
Operating Income
-11.48-17.25-7.51-17.10.07
Upgrade
Interest Expense
----0.02-0.01
Upgrade
Interest & Investment Income
0.380.740.790.320.22
Upgrade
Currency Exchange Gain (Loss)
-0.37-0.08-0.29-0.12-0.04
Upgrade
Other Non Operating Income (Expenses)
-0.02-0.02-0.01-0.01-0
Upgrade
Pretax Income
-11.49-16.61-7.02-16.930.24
Upgrade
Net Income
-11.49-16.61-7.02-16.930.24
Upgrade
Net Income to Common
-11.49-16.61-7.02-16.930.24
Upgrade
Shares Outstanding (Basic)
1211111110
Upgrade
Shares Outstanding (Diluted)
1211111112
Upgrade
Shares Change (YoY)
6.54%0.57%3.23%-7.80%73.76%
Upgrade
EPS (Basic)
-0.94-1.45-0.62-1.530.02
Upgrade
EPS (Diluted)
-0.94-1.45-0.62-1.530.02
Upgrade
Free Cash Flow
-9.45-14.58-3.72-14.971.07
Upgrade
Free Cash Flow Per Share
-0.77-1.27-0.33-1.360.09
Upgrade
Gross Margin
64.78%-215.53%81.83%-33.78%87.18%
Upgrade
Operating Margin
-484.31%-3349.71%-68.55%-5718.06%0.42%
Upgrade
Profit Margin
-484.56%-3225.05%-64.05%-5660.53%1.52%
Upgrade
Free Cash Flow Margin
-398.44%-2830.29%-33.92%-5007.36%6.86%
Upgrade
EBITDA
-10.57-16.21-6.41-16.020.84
Upgrade
EBITDA Margin
---58.49%-5.36%
Upgrade
D&A For EBITDA
0.911.041.11.080.77
Upgrade
EBIT
-11.48-17.25-7.51-17.10.07
Upgrade
EBIT Margin
---68.55%-0.42%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.